Abstract：
OBJECTIVE: Despite increasingly refined tools for identifying individuals at clinical high-risk for psychosis (CHR-P), less is known about the effectiveness of CHR-P interventions. The significant clinical heterogeneity among CHR-P individuals suggests that interventions may need to be personalized during this emerging illness phase. We examined longitudinal trajectories within-persons during treatment to investigate whether baseline factors predict symptomatic and functional outcomes.
METHODS: A total of 36 CHR-P individuals were rated on attenuated positive symptoms and functioning at baseline and each week during CHR-P step-based treatment.
RESULTS: Linear mixed-effects models revealed that attenuated positive symptoms decreased during the study period, while functioning did not significantly change. When examining baseline predictors, a significant group-by-time interaction emerged whereby CHR-P individuals with more psychiatric comorbidities at baseline (indicating greater clinical complexity) improved in functioning during the study period relative to CHR-P individuals with fewer comorbidities.
CONCLUSIONS: Individual differences in clinical complexity may predict functional response during the early phases of CHR-P treatment.
METHODS: A total of 36 CHR-P individuals were rated on attenuated positive symptoms and functioning at baseline and each week during CHR-P step-based treatment.
RESULTS: Linear mixed-effects models revealed that attenuated positive symptoms decreased during the study period, while functioning did not significantly change. When examining baseline predictors, a significant group-by-time interaction emerged whereby CHR-P individuals with more psychiatric comorbidities at baseline (indicating greater clinical complexity) improved in functioning during the study period relative to CHR-P individuals with fewer comorbidities.
CONCLUSIONS: Individual differences in clinical complexity may predict functional response during the early phases of CHR-P treatment.
摘要：
目标：尽管识别临床精神病高危人群（CHR-P）的工具越来越完善，对CHR-P干预措施的有效性知之甚少。CHR-P个体之间的显著临床异质性表明，在这个新出现的疾病阶段，干预措施可能需要个性化。我们检查了治疗期间人体内的纵向轨迹，以调查基线因素是否可以预测症状和功能结果。
方法：总共36名CHR-P个体在基线时和在CHR-P步骤为基础的治疗期间每周对其减弱的阳性症状和功能进行了评估。
结果：线性混合效应模型显示，在研究期间，减弱的阳性症状减少，而功能没有明显变化。在检查基线预测因子时，出现了显著的按时间分组的交互作用,因此,在研究期间,相对于合并症较少的CHR-P个体,基线时精神病合并症较多(表明临床复杂性较大)的CHR-P个体的功能得到改善.
结论：临床复杂性的个体差异可以预测CHR-P治疗早期阶段的功能反应。
方法：总共36名CHR-P个体在基线时和在CHR-P步骤为基础的治疗期间每周对其减弱的阳性症状和功能进行了评估。
结果：线性混合效应模型显示，在研究期间，减弱的阳性症状减少，而功能没有明显变化。在检查基线预测因子时，出现了显著的按时间分组的交互作用,因此,在研究期间,相对于合并症较少的CHR-P个体,基线时精神病合并症较多(表明临床复杂性较大)的CHR-P个体的功能得到改善.
结论：临床复杂性的个体差异可以预测CHR-P治疗早期阶段的功能反应。
